Onkologie. 2017:11(6):300-305 | DOI: 10.36290/xon.2017.055

Multiple myeloma and differential diagnostic of back pain

Lenka Szeligová, Hana Plonková, Tomáš Jelínek, Roman Hájek
Klinika hematoonkologie, FN Ostrava

Multiple myeloma is a malignant hematological disease, falling under the group of monoclonal gamapathies, which are characterizedby the presence of monoclonal immunoglobulin in blood serum and/or in urine. For the diagnosis itself an increasednumber of clonal plasmocytes in bone marrow is needed. Another diagnostic marker is organ damage, also known under theacronym CRAB – hypercalcemia (calcium), renal insufficiency, anemia and bone damage. Myeloma tend to be accompanied byskeletal damage, the so-called myeloma bone disease is prevalent in as many as 80 % of cases. The presence of osteolytic lesions,or even pathological fractures is a typical phenomenon. Damage to the skeleton may be very severe and early diagnosis may helpin preventing serious life quality decrease for patients, who otherwise have a well treatable disease with a long-term prognosis.Therefore, when treating patients with back pain which does not disappear in under one month, or which has a worsening tendencyin spite of usual analgetic treatment, in patients with no trauma history or in the presence of other warning signs showinga possible malignant disease (increased fatigue, weight loss, loss of appetite, high-intensity pain), a fast diagnosis is needed. It isnecessary, as soon as possible, to examine the patient by means of a more precise imaging technique than a standard x-ray (a CT,or an MRI scan) and to perform further laboratory tests to find the source of patient‘s difficulties.

Keywords: multiple myeloma, skeletal damage, osteolytic lesions

Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Szeligová L, Plonková H, Jelínek T, Hájek R. Multiple myeloma and differential diagnostic of back pain. Onkologie. 2017;11(6):300-305. doi: 10.36290/xon.2017.055.
Download citation

References

  1. Palumbo A, Anderson K. Multiple myeloma. N. Engl. J. Med. 2011; 364: 1046-1060. Go to original source... Go to PubMed...
  2. Barlogie B, Mitchell A, van Rhee F, et al. Curing myeloma at last: defining criteria and providing the evidence. Blood 2014; 124(20): 3043-3051. Go to original source... Go to PubMed...
  3. Kumar SK, Dispenzieri A, Lacy MD, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28(5): 1122-1128. Go to original source... Go to PubMed...
  4. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78: 21-33. Go to original source... Go to PubMed...
  5. Hájek R, Adam Z, Ščudla V, et al. Diagnostika a léčba mnohočetného myelomu. Transfuze a hematologie dnes 2012; 18(Suppl. 1): 17-22.
  6. Adam Z, Krejčí M, Vorlíček J, et al. Hematologie. Přehled maligních hematologických nemocí. Praha: Grada 2008: 392 s.
  7. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9. Go to original source... Go to PubMed...
  8. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15: e538-e548. Go to original source... Go to PubMed...
  9. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009; 23: 1545-1556. Go to original source... Go to PubMed...
  10. Terpos E, Dimopoulos MA. Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications. Cancer Immunol Immunother. 2011; 60(3): 305-317. Go to original source... Go to PubMed...
  11. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009; 23: 435-441. Go to original source... Go to PubMed...
  12. Adam Z, Bednařík J, Neunauer J, et al. Mnohočetný myelom a diferenciální diagnostika bolestí páteře. Prakt Lék 2006; 86(7): 396-410.
  13. Terpos E, Moulopoulos LA, Dimopoulos MA. Advances in imaging and the management of myeloma bone disease. Journal of Clinical Oncology 2011; 29: 1907-1915. Go to original source... Go to PubMed...
  14. Gleeson TG, Moriarty J, Shortt CP, et al. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiology 2009; 38: 225-236. Go to original source... Go to PubMed...
  15. Ippolito D, Besostri V, Bonaffini PA, et al. Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM). European Journal of Radiology 2013; 82: 2322-2327. Go to original source... Go to PubMed...
  16. Pianko MJ, Terpos E, Roodman GD, et al. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease. Clinical Cancer Research 2014; 20: 5888-5897. Go to original source... Go to PubMed...
  17. Plonkova H, Miklosova K, Jelinek T, et al. Comparison of whole-body low-dose computed tomography and conventional radiography in the staging of multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia 2015; 15(Suppl. 3): e120, abstr. PO-071. Go to original source...
  18. Kröpil P, Fenk R, Fritz LB, et al. Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol. 2008; 18: 51-58. Go to original source... Go to PubMed...
  19. Mysliveček M, Nekula J, Bačovský J. Zobrazovací metody v diagnostice a sledování mnohočetného myelomu. Vnitř Lék 2006; 52(S2): 46-54. Go to PubMed...
  20. Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007; 25: 1121-1128. Go to original source... Go to PubMed...
  21. Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011; 117: 4701-4705. Go to original source... Go to PubMed...
  22. Agarwal A, Chirindel A, Shah BA, et al. Evolving role of FDG PET/CT in multiple myeloma imaging and management. AJR Am J Roentgenol. 2013; 200: 884-890. Go to original source... Go to PubMed...
  23. Terpos E, Dimopoulos MA, Moulopoulos LA. The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. ASCO Educational Book 2016: 407-417. Go to original source...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.